Skip to main content
SHIFT Newsroom

Semaglutide results: timelines and review points

Decorative semaglutide timeline title card

There is no week when everyone should first feel or see semaglutide working. Appetite, weight and side effects vary, and a study's end date is not a personal deadline. This guide explains the 68-week STEP 1 result, how to keep useful records and when to raise concerns. The injection study discussed here should not be treated as evidence for an identical tablet timeline.


Key points

- Trial averages cannot predict a particular person's weekly results.
- Dose schedules depend on the product and your prescribed plan.
- A 68-week research endpoint is not a reason to delay a review.
- Symptoms may need urgent attention at any stage.
- Record your experience and discuss concerns with your own prescriber.

Why a week-by-week promise is misleading

Some people notice changes in appetite before a sustained change on the scales, while others have a different experience. Neither a strong appetite effect nor nausea proves that treatment is effective or safe. Conversely, not feeling an immediate change does not establish treatment failure. Use your agreed review plan and raise concerns rather than comparing yourself with a fixed internet timetable.

The STEP 1 study used a gradual escalation to once-weekly injected semaglutide 2.4 mg. Trial participants followed a defined protocol. In practice, symptoms, interruptions and individual decisions can affect treatment. Even two people on the same dose can respond differently, so a friend's week-by-week account is not a reliable benchmark.

A more useful way to organise the treatment period is:

  1. Before starting: understand the exact product, prescription instructions, contact arrangements and review plan.
  2. During dose changes: record the prescribed dose and any symptoms; ask for advice before making changes yourself.
  3. At planned reviews: assess benefits, tolerability and whether the plan remains appropriate.
  4. Between reviews: contact the service about concerns, especially poor intake, persistent symptoms or lack of progress.
  5. When reading research: check the study population, product, dose and endpoint before comparing its results with your own.

Weight can fluctuate and a slower period does not by itself establish why progress has changed. A trend over time is more informative than a single reading. Do not automatically cut food further or increase medicine in response to a plateau; review the situation with your care team.

Why your semaglutide weight loss progress may differ from average trial figures

Trial averages describe a group, not a person, and several factors pull individual timelines away from that average.

Pro Tip: Track your progress against your own baseline, not against someone else's photos or a trial average: your starting weight, dose and diabetic status all mean your timeline is genuinely your own.

What the UK clinical pathway means for your titration schedule

Semaglutide is prescription-only in the UK, and that single fact shapes almost everything about how the timeline actually runs in practice. It isn't something you start and adjust on your own; it comes with a clinical assessment, a structured titration schedule and scheduled check-ins.

  1. Assessment: a prescriber considers suitability and explains the specific product.
  2. Prescription instructions: follow the agreed schedule and ask about symptoms or interruptions before changing it.
  3. Review timing: confirm when the service will review you and how to get earlier help.
  4. Continuation decisions: assess benefits and risks individually, alongside any separate NHS funding criteria.

Practical questions include storage, administration, missed doses and contact arrangements. For injections, ask about sharps disposal. Tell the anaesthetic team about treatment before surgery or deep sedation. Pregnancy and contraception advice should be medicine-specific where relevant. NHS access routes also vary between UK nations; a regional Scottish protocol is not a UK-wide prescribing rule.

What STEP 1 actually measured

STEP 1 studied adults with overweight or obesity without diabetes. Both groups received lifestyle support; one group received injected semaglutide 2.4 mg weekly and the other placebo. Its results describe that study population and treatment, not SHIFT patients or a men-only trial.

The STEP 1 report reported average weight changes at 68 weeks of −14.9% with semaglutide and −2.4% with placebo. Individuals varied. These figures do not promise that you will lose the average amount, reach it by a particular month or follow a straight line towards it.

A trial endpoint is chosen so researchers can compare groups. It is not a definition of when a medicine has 'fully worked', and it does not set the date of your first clinical review. Ask which outcomes matter for your own care and how they will be assessed. Weight, tolerability and relevant health measures may all enter that discussion.

Side effects and safety checks that shape your timeline

Digestive symptoms can occur during treatment and dose escalation, but there is no guaranteed settling period. Tell your prescriber if symptoms persist, worsen or interfere with eating and drinking. Severe symptoms need assessment rather than reassurance that they are simply part of a timetable.

The UK Wegovy product information describes safety precautions and individual continuation decisions. It calls for a benefits-and-risks decision when adult weight loss is below 5% after six months of treatment. That interval starts with treatment, not after reaching maintenance. It does not mean waiting six months to report symptoms.

How to track progress and respond if results are slower than expected

A short record can make a review more useful. Note the date, prescribed dose, weight if you are tracking it, symptoms and whether you can eat and drink normally. Include questions you want answered. Measurements taken under similar conditions are easier to compare, but you do not need constant weighing to justify asking for help.

  1. Use consistent records: avoid comparing different scales or isolated readings as if they were precise trends.
  2. Record tolerability: note when symptoms began and what they prevent you doing.
  3. Contact the right service: urgent symptoms need urgent care; routine concerns can go to your prescriber.
  4. Agree the next review: ask what information the clinician needs and what should trigger earlier contact.

Pro Tip: Pair the medication with consistent behavioural support: the trial evidence behind semaglutide was generated alongside diet and activity counselling, not the drug on its own.

Sources

FAQ

How much weight will I lose in 2 months on semaglutide?

There is no reliable personal two-month prediction. Early treatment may still involve dose changes, depending on the product and plan. Record your experience and ask your prescriber about concerns; the 68-week trial average cannot be converted into an expected monthly loss.

How quickly do you lose weight on semaglutide?

There is no universal onset or rate. Appetite and weight can change differently between people. An exact four-to-twelve-week promise is not established by the study result discussed here.

How many weeks to see results from semaglutide?

STEP 1 assessed its main outcome at 68 weeks, but that is a research endpoint, not a deadline for seeing a result. Your care team should set appropriate reviews and explain when to contact them sooner.

I am 8 weeks on semaglutide and I haven't lost any weight. Is this normal?

Raise the concern with your prescriber. They can review the product, actual treatment history, symptoms and relevant health factors. Do not increase the dose or restrict food aggressively to catch up with an online timeline.

What My Timber can help with

Record your actual experience instead of comparing each week with a promised timeline. Ask your own prescriber what they expect from your particular medicine, dose and circumstances.

My Timber provides everyday support with food, movement, personal goals and progress records. It does not prescribe medicines, decide doses or provide a clinical review. Medicine assessment, prescribing, dispensing and treatment monitoring belong with your appropriately regulated healthcare provider.

SHIFT's medicine ordering remains closed while a prescribing partner is being commissioned. This page is information, not an invitation to buy prescription medicine or book a SHIFT prescribing assessment.

Editorial correction — 2 October 2026

We removed unsupported descriptions of SHIFT clinical services and unapproved personal attribution where present. This correction does not represent an independent clinical review of the whole article.

Source and editorial correction — 3 October 2026

This revision corrects unsupported timelines, universal rules and clinical claims, distinguishes study findings from personal expectations, and clarifies service boundaries. Original publication history is retained. This is an editorial source review, not independent clinical certification.

Related: Weight-management review: questions to take with you | SHIFT.

Last updated .